Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Policy & Regulation

New National Security Checks Could Hinder Investment, Warns UK Biotech Sector

Life science SMEs and their investors need to comply with new UK government checks on their dealmaking.

Companies Commercial Regulation

Novo Nordisk On The Pluses And Minuses Of The UK Post-Brexit R&D Environment

Post-Brexit Britain offers a fertile R&D ecosystem, but it needs to improve uptake in novel medicines there and strike a lasting deal with the EU over batch testing, Novo Nordisk’s UK general manager Pinder Sahota tells Scrip.

Brexit Clinical Trials Companies

Policy

Set Alert for Policy

Latest From Policy

Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative

South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.

South Korea Artificial Intelligence

Stay Or Exit? Global Health Players Ponder New China Trajectory

It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.

China Business Strategies

GSK Is Third Major Inhaler Maker To Cap Copays; Will Teva Follow?

It might make sense from a competitive standpoint for Teva to join the trend. That’s the way it happened in the insulin category.

Reimbursement Pricing Strategies

China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes

The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.

China United States

WuXi AppTec Quits BIO As Group Endorses BIOSECURE Act

BIO chairman Ted Love had said at BIO CEO last month that “damaging” the company could have unintended consequences.

China Legislation

China Lowers GDP Target As VBP And Corruption In Focus At 'Two Sessions'

Amid slack domestic consumption and declining overseas demand, 2024 may be the start of a multi-year slowing in growth for the world’s second-largest economy. In the health sector, volume-based procurement continues to expand while the focus of anti-corruption campaigns appears to be changing.

China Policy
See All

Regulation

Set Alert for Regulation

Latest From Regulation

Pipeline Watch: Six Approvals And 15 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Watch: 26 Approvals And 11 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Conflicts Of Interest Delay Leqembi’s EU Approval

Eisai/Biogen’s Alzheimer’s drug has fallen foul of a recent court ruling over the handling of the European Medicines Agency’s experts' competing interests.

Approvals Neurology

India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’

Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.

India Intellectual Property

Could Cash-Strapped Idorsia Really Go It Alone With Newly Approved Tryvio?

CEO Jean-Paul Clozel insists Idorsia could launch the first-in-class hypertension drug alone, but analysts think a deal will be done soon – with the only question being for how much.

Approvals Cardiovascular

Pipeline Watch: 16 Approvals And 21 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All
UsernamePublicRestriction

Register